SCHEDULE 13G/A: Thomas A. Satterfield, Jr. Discloses 5.9% Passive Stake in OS Therapies Incorporated

Thomas A. Satterfield, Jr. has filed an amended Schedule 13G, reporting a 5.9% beneficial ownership stake in OS Therapies Incorporated as of December 31, 2024.

Summary

• Thomas A. Satterfield, Jr. beneficially owns an aggregate of 1,267,465 shares of OS Therapies Incorporated common stock.
• This ownership represents 5.9% of the company's outstanding common stock.
• The percentage is calculated based on 21,238,378 shares of common stock outstanding as of November 11, 2024, as reported by the issuer in its Quarterly Report on Form 10-Q for the fiscal quarter ended September 30, 2024.
• The beneficial ownership includes 954,965 shares of common stock and 156,250 units ("Units").
• Each Unit is comprised of one share of Series A Senior Convertible Preferred Stock (convertible initially on a one-for-one basis) and a warrant to purchase one share of common stock at an initial exercise price of $4.40 per share.
• Mr. Satterfield holds sole voting power and sole dispositive power over 61,215 shares.
• Mr. Satterfield holds shared voting power and shared dispositive power over 1,206,250 shares.
• The filing states that the securities were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer.

Sentiment

Score: 7

Explanation: The disclosure of a significant passive stake by an individual investor, especially one that includes convertible securities and warrants, can be viewed positively as it signals confidence and a long-term investment perspective in the company.

Positives

• The disclosure of a significant passive stake (5.9%) by an individual investor, Thomas A. Satterfield, Jr., may signal confidence in OS Therapies Incorporated's long-term prospects.
• The investor's stake includes convertible preferred stock and warrants, indicating a potential for increased common stock ownership and a long-term investment horizon.

Future Outlook

This Schedule 13G filing is a disclosure of current beneficial ownership and does not contain forward-looking statements or guidance regarding the company's future performance, strategic direction, or operational outlook.

Management Comments

• The filing includes a certification from Thomas A. Satterfield, Jr. stating that 'to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.'

Industry Context

This filing is a standard regulatory disclosure of a significant passive ownership stake by an individual investor. It does not provide specific insights into broader industry trends but reflects an investor's confidence in OS Therapies Incorporated within its sector.

Comparison to Industry Standards

• This document is a standard Schedule 13G filing, which is a regulatory requirement for passive investors acquiring more than 5% of a company's stock. It does not contain information that allows for a direct comparison of OS Therapies Incorporated's operational or financial results against industry benchmarks or specific comparable companies or projects.

Related Party Transactions

• Thomas A. Satterfield, Jr. holds shares through entities he controls: 100,000 shares (issuable upon conversion of Units) are held by Tomsat Investment & Trading Co., Inc., a corporation controlled by Mr. Satterfield.
• 162,500 shares (issuable upon conversion of Units) are held by A.G. Family L.P., a partnership managed by a general partner controlled by Mr. Satterfield.
• 943,750 shares are held by Satterfield Vintage Investments, L.P., where Tomsat Investment & Trading Co., Inc. and A.G. Family L.P. jointly own a majority of its equity, and Tomsat Investment & Trading Co., Inc. is the general partner.

Stakeholder Impact

• Shareholders: Provides increased transparency regarding significant ownership stakes, potentially signaling investor confidence and a stable shareholder base due to a large passive investment.

Key Dates

Keywords

OS Therapies Incorporated, Thomas A. Satterfield Jr., Schedule 13G, Beneficial Ownership, Common Stock, Series A Preferred Stock, Warrants, SEC Filing, Passive Investment, Shareholder Stake, Investment Disclosure